Barclays’s LakeShore Biopharma LSB Stock Holding History

Barclays’s Portfolio LSB Stock Details LSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-24,757	Closed	-$18.1K	–	5785
2025 Q3	$18.1K	Hold	24,757	–	–	﹤0.01%	4957
2025 Q2	$25.3K	Hold	24,757	–	–	﹤0.01%	4815
2025 Q1	$60.7K	Hold	24,757	–	–	﹤0.01%	4571
2024 Q4	$85.7K	Sell	24,757 -1	-0%	-$3	﹤0.01%	4631
2024 Q3	$169K	Hold	24,758	–	–	﹤0.01%	4377
2024 Q2	$160K	Buy	+24,758	New	+$202K	﹤0.01%	3689
2023 Q4	–	Sell	-569	Closed	-$4.55K	–	5370
2023 Q3	$4.55K	Sell	569 -10,320	-95%	-$119K	﹤0.01%	4396
2023 Q2	$150K	Buy	+10,889	New	+$161K	﹤0.01%	3388

Barclays's LSB Position: Q4 2025 in Review

Barclays sold out of LakeShore Biopharma (LSB) in Q4 2025, closing a stake of 24,757 shares — an estimated $18.1K sold.

Barclays first reported a position in LSB in Q2 2023 and held it in 8 quarters. The position peaked at $169K in Q3 2024. 0 funds tracked by Wall St. Rank hold LSB as of Q4 2025.

Barclays reported no remaining LakeShore Biopharma position as of Q4 2025 after selling out during the quarter.
Barclays sold 24,757 LakeShore Biopharma shares in Q4 2025, an estimated $18.1K.
Barclays first reported a position in LakeShore Biopharma in Q2 2023 and held it in 8 quarters.
Barclays's LakeShore Biopharma position peaked at $169K in Q3 2024.
0 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.